For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Hybridon, Inc.

USPTO Granted Patents = 98

Trademarks = 3

Forward Citations = 3,589

Loading Chart...

Loading Chart...

72 inventors (with patents filed for the assignee):

Sudhir Agrawal (53 out of 152 patents)

Radhakrishnan P Iyer (13 out of 37 patents)

Dong Yu (11 out of 66 patents)

4. John Goodchild (11 out of 11 patents)

5. Gregory S Robinson (11 out of 12 patents)

6. Ivan Habus (11 out of 11 patents)

7. Jin-Yan Tang (8 out of 17 patents)

8. Ekambar R Kandimalla (6 out of 76 patents)

9. Qiuyan Zhao (6 out of 15 patents)

10. Ruiwen Zhang (6 out of 6 patents)

11. Aharon S Cohen (6 out of 15 patents)

12. Thomas E Leonard (6 out of 6 patents)

13. Eric Von Hofe (5 out of 7 patents)

14. Theresa Devlin (5 out of 5 patents)

15. Bruce L Frank (4 out of 4 patents)

Core Competencies:

Oligonucleotides

Antisense Oligonucleotides

Gene Expression Modulation

Tumor Growth Inhibition

CpG-Mediated Immune Stimulation

Modified VEGF Oligonucleotides

Drug-Resistant Bacteria

HPV-Specific Oligonucleotides

Phosphorothioates

Alkylphosphonate Synthesis

Neovascularization Inhibition

Affinity-Based Purification

98 patents: Sort by Forward Citations

1. 6984729 - Oligonucleotides specific for hepatitis B virus (2006-01-10),

2. 6946447 - MDM2-specific antisense oligonucleotides (2005-09-20),

3. 6936593 - Method of down-regulating gene expression (2005-08-30),

4. 6815429 - Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides (2004-11-09),

5. 6667293 - Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response (2003-12-23),

6. 6649596 - Modified VEGF Oligonucleotides for Inhibition of tumor growth (2003-11-18),

7. 6645943 - Method of down-regulating gene expression (2003-11-11),

8. 6624293 - Modified protein kinase A-specific oligonucleotides and methods of their use (2003-09-23),

9. 6608035 - Method of down-regulating gene expression (2003-08-19),

10. 6605708 - Building blocks with carbamate internucleoside linkages and oligonucleotides derived therefrom (2003-08-12),

11. 6531589 - Base protecting groups and synthons for oligonucleotide synthesis (2003-03-11),

12. 6509459 - Base protecting groups and rapid process for oligonucleotide synthesis (2003-01-21),

13. 6509149 - HPV-specific oligonucleotides (2003-01-21),

14. 6489464 - Branched oligonucleotides as pathogen-inhibitory agents (2002-12-03),

15. 6489304 - Hyperstructure-forming carriers (2002-12-03),

Hybridon, Inc. is a leading biotechnology company specialized in the development of innovative RNA-based therapies. With our cutting-edge technology and expertise, we are dedicated to advancing the field of drug discovery and improving patient outcomes. Visit our website to learn more about our groundbreaking research and the latest advancements in RNA therapeutics.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

98 Patents

#28 in Cambridge, MA

#207 in Massachusetts

#3,717 in US

#7,688 in the World

Cambridge, MA, United States of America

Hybridon, Inc.

Forward Citations = 3,589

72 inventors:

Sudhir Agrawal (53 out of 152 patents)

Radhakrishnan P Iyer (13 out of 37 patents)

Dong Yu (11 out of 66 patents)

4. John Goodchild (11 out of 11 patents)

5. Gregory S Robinson (11 out of 12 patents)

Please report any incorrect information to support@idiyas.com

Loading…